Rivastigmine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Rivastigmine

Examples of brand names: Exelon [EU/DE]

ATC code: N06DA03

Main use (for orientation): Dementia

Documented research summary

Randomised six-arm crossover study, n=15: 3 mg rivastigmine attenuated cannabis-induced impairment of delayed recall; immediate recall showed only a trend. CBD/rivastigmine additionally showed stronger effects than either alone in a scopolamine mouse model; this cannot be extrapolated to patients.

Uncertainties and limitations

Documented individual title/abstract review with selected relevant full texts; not an exhaustive worldwide systematic review and no independent human professional approval. Missing data do not establish safety. All 28 cannabinoids define the search scope, not 28 clinically studied pairs per active substance.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

Cannabis; inhaled preparation – clinically investigated

Finding ID: B0469

Type of result: Context-specific finding

Observation: Rivastigmine improved delayed recall; immediate recall showed only a trend.

Mechanism: Modification of cannabis-related memory effects by vardenafil or rivastigmine.

Study type: Double-blind human crossover experiment, pharmacodynamics

Context studied: 15 people, six conditions; vardenafil 20 mg or rivastigmine 3 mg.

Clinical interpretation: Human endpoint directly studied under narrowly defined study conditions; long-term safety and generalisability not established.

Limitations and uncertainties: Small acute experiment, not a long-term treatment or safety recommendation. Ambiguous cannabis mass in the abstract not treated as a THC dose.

Original sources for this finding: Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. [VF_P_24998257]

CBD – laboratory and animal studies

Finding ID: B0479

Type of result: Context-specific finding

Observation: CBD together with rivastigmine improved the passive avoidance test more than either treatment alone.

Mechanism: Combination in the scopolamine model of memory impairment.

Study type: Mouse experiment, pharmacodynamics

Context studied: Acute intraperitoneal CBD 1 mg/kg and rivastigmine 0.5 mg/kg; relevant full-text sections of PMC11206614 read.

Clinical interpretation: Applicability to humans is unresolved; preclinical endpoint, not clinical evidence of treatment efficacy or safety.

Limitations and uncertainties: Animal model and behavioural test, not a clinical Alzheimer's combination or human pharmacokinetics.

Original sources for this finding: The Influence of an Acute Administration of Cannabidiol or Rivastigmine, Alone and in Combination, on Scopolamine-Provoked Memory Impairment in the Passive Avoidance Test in Mice. [VF_P_38931476]

References and access status

[VF_L_D0415] RIVASTIGMINE TARTRATE (RIVASTIGMINE TARTRATE ) CAPSULE [DR. REDDY'S LABORATORIES LIMITED]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2019

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_24998257] Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.

Original source / bibliographic reference

Authors: Theunissen EL, Heckman P, de Sousa Fernandes Perna EB, Kuypers KP, Sambeth A, Blokland A, Prickaerts J, Toennes SW, Ramaekers JG.

Year: 2015

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1007/s00213-014-3667-2

PMID: 24998257

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[VF_P_38931476] The Influence of an Acute Administration of Cannabidiol or Rivastigmine, Alone and in Combination, on Scopolamine-Provoked Memory Impairment in the Passive Avoidance Test in Mice.

Original source / bibliographic reference

Authors: Kruk-Slomka M, Slomka T, Biala G.

Year: 2024

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.3390/ph17060809

PMID: 38931476

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility